 "SRL Diagnostics, Agilus Diagnostics, Anand K, marketing spend, pharma")
(This report has been updated) Nearly two years after its rebranding, Agilus Diagnostics (formerly SRL Diagnostics) is now confident about reducing marketing expenses initially undertaken to create awareness around the name change. From nearly 5 per cent of revenue in 2024-25 (FY25), marketing spend is expected to decrease to 2.5-3 per cent in 2025-26, a senior executive said.
Speaking to Business Standard, Anand K, managing director and chief executive officer of Agilus, which rebranded in May 2023, said that while some marketing expenditure will continue in the fourth quarter of FY25 and first quarter of 2025-26 (FY26), spending is
